WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.


L04 IMMUNOSUPPRESSANTS

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.


L04A IMMUNOSUPPRESSANTS

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.


L04AC Interleukin inhibitors

Interleukin inhibitors used in asthma are classified in R03DX.
Dupilumab is classified in D11AH.

The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.
The DDD for daclizumab is based on the treatment of multiple sclerosis.
The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.


    ATC code  Name  DDD  U Adm.R Note
    L04AC17 tildrakizumab 1.11 mg P 

List of abbreviations

Last updated: 2024-01-26